Initial data for the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9 expected in second quarter of 2025 Dosing in the Heart-2 trial has moved to the 0.6 mg/kg cohort VERVE-301 nominated as development candidate targeting the LPA gene; Verve to receive an associated milestone payment from Eli Lilly Well-capitalized with cash runway extending into mid-2027 Company to present at 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 2:15 p.m. ET/11:15 a.m. PT BOSTON, Ja ...